Prostatic Hyperplasia

• 

  Subject Areas on Research

  • 5α-reductase inhibitors: preventing the treatable. 
  • A coaxial microwave applicator for transurethral hyperthermia of the prostate. 
  • A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. 
  • A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. 
  • A pilot study for a randomized controlled trial comparing the efficacy, safety and cost-effectiveness of surgical treatments of the prostate. 
  • A transgenic mouse prostate cancer model. 
  • Acute urinary retention associated with prostatic carcinoma. 
  • Alpha 1-adrenergic receptor regulation: basic science and clinical implications. 
  • Alpha1-adrenergic blockers and intraoperative floppy-iris syndrome. 
  • Alternative methods for management of prostatic outflow obstruction. 
  • Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. 
  • Aspiration biopsy of prostate. 
  • Associations of benign prostatic hyperplasia with prostate cancer: the debate continues. 
  • Basal cell hyperplasia in the peripheral zone of the prostate. 
  • Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. 
  • Benign prostatic hyperplasia. New concepts in the 1990s. 
  • Benign prostatic hyperplasia: diagnosis and treatment. Benign Prostatic Hyperplasia Guideline Panel. Agency for Health Care Policy and Research. 
  • Benign prostatic hypertrophy and uterine leiomyomas: analogous or dissimilar diseases? 
  • Blue Vision (Cyanopsia) Associated With TURP Syndrome: A Case Report. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • Chronic urinary tract infection due to Candida utilis. 
  • Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. 
  • Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. 
  • Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. 
  • Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. 
  • Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. 
  • Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. 
  • Discounting surgical benefits. Enucleation versus resection of the prostate. 
  • Diseases of the prostate. 
  • Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. 
  • Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. 
  • Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH. 
  • Duodenal glucagonoma: a case report. 
  • E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. 
  • Effects of androgen deprivation on prostate alpha 1-adrenergic receptors. 
  • Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. 
  • Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. 
  • Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. 
  • Evaluation of research needs in nephrology in urology. Obstructive and neuromuscular disorders affecting the urinary system. 
  • Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. 
  • Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. 
  • Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. 
  • Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. 
  • Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials. 
  • In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. 
  • In vitro cultivation of prostatic epithelium. 
  • Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction. 
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. 
  • Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. 
  • Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence. 
  • Lifestyle and lower urinary tract symptoms: what is the correlation in men? 
  • Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. 
  • Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. 
  • Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. 
  • Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). 
  • Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. 
  • Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. 
  • Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. 
  • Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. 
  • Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Morphologic and immunologic studies of human prostatic carcinoma. 
  • Obesity and prostate enlargement in men with localized prostate cancer. 
  • Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. 
  • Oncornavirus-like protein expression in human prostatic tissue. 
  • PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. 
  • Panurethral stricture after photovaporization of the prostate for benign prostatic hyperplasia. 
  • Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. 
  • Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. 
  • Potential selection bias in a community-based study of PSA levels in African-American men. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer early detection practices among men with a family history of disease. 
  • Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. 
  • Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. 
  • Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. 
  • Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. 
  • Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. 
  • Prostatic disorders: MR imaging at 1.5 T. 
  • Pseudohyperplastic prostatic adenocarcinoma. 
  • Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. 
  • Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. 
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. 
  • Relationship of serum sex-steroid hormones and prostate volume in African American men. 
  • Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. 
  • Risk factors for delayed hematuria following photoselective vaporization of the prostate. 
  • Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. 
  • Scanning and transmission electron microscopy of human prostatic acinar cells. 
  • Scanning electron microscopy of hyperplastic and neoplastic human prostate. 
  • Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. 
  • Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. 
  • Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. 
  • Tamsulosin and the intraoperative floppy iris syndrome. 
  • Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. 
  • The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. 
  • The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. 
  • The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. 
  • The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. 
  • The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. 
  • Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. 
  • Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. 
  • Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. 
  • Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. 
  • Urodynamic predictors of outcomes with photoselective laser vaporization prostatectomy in patients with benign prostatic hyperplasia and preoperative retention. 
  • Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. 
  • alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. 
• 

  Keywords of People

  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery